Mangalam Drugs Share Price Drop Analyzed

Mangalam Drugs’ stock price fell significantly on September 25, 2025, hitting a lower circuit at ₹29.54 per share. This drop is concerning because it happened after a series of large stock trades. The BSE Sensex, meanwhile, was rising, showing the overall market is doing well.

Key Points

• Large stock trades triggered a rapid price decline for Mangalam Drugs.
• Bulk deals involving Tata Capital and other brokers impacted the stock.
• The overall market (BSE Sensex) is performing positively currently.
• Mangalam Drugs specializes in manufacturing key medicines ingredients.
• Promoters own a significant 50.36% of the company’s shares.
• The company has a strong global reputation and leading market position.

The main reason for the drop is the activity of several large stock trades. Tata Capital sold a big amount of shares, and other brokers also made significant trades. These actions created downward pressure on Mangalam Drugs’ stock price.

Bulk Deal Details

Here’s a breakdown of the key bulk deals:

• Tata Capital: Sold 4,44,316 shares at ₹33.54 per share.
• Tata Capital: Sold 105,000 shares at ₹33.36 per share.
• Limited Badjate Stock Broking: Sold 4,00,000 shares at ₹32.86 per share.
• Gaurav Chandrakant Shah: Bought 1,75,000 shares at ₹34.17 per share.
• Mansi Share and Stock Broking: Bought 4,30,755 shares at ₹32.68 per share and sold 2,50,749 shares at ₹33.55 per share.
• Share India Securities: Bought 1,90,820 shares at ₹33.22 per share and sold 1,60,820 shares at ₹32.71 per share.

Mangalam Drugs is a company that has been making medicines ingredients since 1977. They have a research lab that is recognized by the Indian government. They are known around the world for certain medicines they produce, and they’re one of the biggest companies making them.

Takeaway: This sudden drop in price signals a potential need for further investigation into the market forces influencing Mangalam Drugs’ stock performance.